2018 Volume 26 Issue 2 Pages 101-104
Although the survival of patients with liver metastases was previously extremely poor, the introduction of novel chemotherapeutic agents, such as oxaliplatin, has increased the median survival of these patients. S-1 has been reported to show strong antitumor activity in various types of cancer, such as colorectal cancer (CRC), and its feasibility in combination with oxaliplatin (SOX) has been reported to have a promising efficacy with fair tolerability in patients with metastatic CRC. We here present a case of synchronous liver metastasis of CRC in which a complete clinical response was successfully achieved by SOX plus bevacizumab (BV). CT scan results confirmed a clinical complete response after eight cycles, and monotherapy with S-1 was ongoing for 6 months. Currently, there was no evidence of any recurrent or metastatic lesions. We found that a regimen of SOX plus BV is a safe and effective treatment for metastatic CRC that does not require central venous access.
